Um novo olhar sobre a extensão da anticoagulação no tromboembolismo venoso
A fresh look at extended-duration anticoagulation after venous thromboembolism
Suzanna Maria Viana Sanches; Monique Magnavita Borba da Fonseca Cerqueira; Marcos Arêas Marques
References
1 Prins MH, Lensing AWA, Prandoni P, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv. 2018;2(7):788-96.
2 Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510.
3 Weitz J, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211-22.
4 Piazza G, Bikdeli B, Pandey AK, et al. Apixaban for extended treatment of provoked venous thromboembolism. N Engl J Med. 2025;393(12):1166-76.
5 Couturaud F, Schmidt J, Sanchez O, et al. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet. 2025;405(10480):725-35.
Submitted date:
05/20/2026
Accepted date:
07/30/2026
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email